重組凝血因子市場規模、佔有率和成長分析（按產品類型、血友病類型、最終用戶和地區分類）—產業預測（2026-2033 年）

預計到 2024 年，重組凝血因子市場規模將達到 149.7 億美元，到 2025 年將達到 160 億美元，到 2033 年將達到 272.9 億美元，預測期（2026-2033 年）的複合年成長率為 6.9%。

由於血友病和其他出血性疾病發病率的上升，以及消費者對血漿衍生療法和重組療法的需求不斷成長，重組凝血因子市場正經歷顯著成長。重組DNA技術的進步使得高效生產關鍵蛋白（如VIII因子、IX因子和血管性血友病因子）成為可能，使其能夠有效地應用於治療。此外，持续的研发活动和不断增加的核准产品也推动了该领域的创新。儘管面臨高昂的治療成本和來自低成本血漿​​替代療法的競爭等挑戰，但血友病預防性治療的日益普及為市場在這一充滿活力的環境中提供了巨大的擴張機遇，而這些重組產品傳播傳染性病原體的風險也相對較低。

重組凝血因子市場成長要素

受制药和生物技术领域研发投入和資金籌措持续增长的推动，重组凝血因子市场正经历显著增长。該市場的主要企業致力於開發先進技術產品，從而促進了重組凝血因子在全球已開發經濟體和新興經濟體的應用。此外，越來越多的創新重組凝血因子產品核可，進一步推動了這個應用擴展趨勢，顯著促進了這些重要治療藥物的全球市場整體擴張。

限制重組凝血因子市場的因素

重組凝血因子市場的成長受到幾個關鍵因素的限制。首先，血友病治療的高成本構成了一大障礙，尤其是在市場上已有價格更為親民的血漿凝血療法的情況下。此外，重組凝血因子替代治療方法的存在也加劇了這項挑戰。隨著患者和醫療機構尋求更具成本效益的解決方案，這些替代療法的競爭可能會限制市場擴張。因此，這些因素使得重組凝血因子的推廣和應用變得更加複雜。

重組凝血因子市場趨勢

全球重組凝血因子市場正經歷顯著成長，這主要得益於血液疾病（尤其是血友病）盛行率的上升，以及先進重組技術在治療方法上的日益普及。與傳統治療方法相比，重組凝血因子具有更高的安全性、更低的病毒感染風險和更強的療效，因此越來越受到患者和醫療機構的青睞。此外，產品配方和給藥方式的持續創新、人們對治療方案認知的不斷提高以及以患者為中心的醫療保健舉措，也進一步推動了市場擴張。這一趨勢反映了全球血液凝固障礙治療方式的動態轉變。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

全球重組凝血因子市場規模（依產品類型及複合年成長率分類）（2026-2033 年）

• 重組因子VIII
• 重組因子IX
• 血管性血友病因子

全球重組凝血因子市場規模（依血友病類型分類）及複合年成長率（2026-2033 年）

• A型血友病A
• B型血友病

全球重組凝血因子市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 研究所

全球重組凝血因子市場規模（依地區分類）及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Novo Nordisk（Denmark）
• Takeda Pharmaceutical Company Limited（Japan）
• Bayer AG（Germany）
• Pfizer Inc.（USA）
• Swedish Orphan Biovitrum AB（Sobi）（Sweden）
• CSL Behring（Australia）
• Roche Holding AG（Switzerland）
• Sanofi（France）
• Grifols, SA（Spain）
• Biogen Inc.（USA）
• Kedrion SpA（Italy）
• Octapharma AG（Switzerland）
• Bio Products Laboratory Ltd.（UK）
• LFB SA（France）
• GC Pharma（South Korea）
• CSL Limited（Australia）
• Freeline Therapeutics（UK）
• Sangamo Therapeutics, Inc.（USA）

結論與建議

Recombinant Coagulation Factors Market size was valued at USD 14.97 Billion in 2024 and is poised to grow from USD 16 Billion in 2025 to USD 27.29 Billion by 2033, growing at a CAGR of 6.9% during the forecast period (2026-2033).

The market for recombinant coagulation factors is experiencing significant growth due to rising incidences of hemophilia and other bleeding disorders, coupled with heightened consumer demand for both plasma-derived and recombinant therapies. Advances in recombinant DNA technology enable efficient production of critical proteins, such as Factor VIII, Factor IX, and von Willebrand factor, leading to effective therapeutic applications. Furthermore, ongoing research and development efforts, along with an increasing number of product approvals, are driving innovation in this sector. While challenges such as high treatment costs and competition from lower-cost plasma alternatives exist, the growing trend toward prophylactic treatments for hemophilia presents substantial opportunities for market expansion in this dynamic landscape, characterized by a decreasing risk of infectious agent transmission from these recombinant products.

Top-down and bottom-up approaches were used to estimate and validate the size of the Recombinant Coagulation Factors market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Recombinant Coagulation Factors Market Segments Analysis

Global Recombinant Coagulation Factors Market is segmented by Product Type, Hemophilia Type, End User and region. Based on Product Type, the market is segmented into Recombinant Factor VIII, Recombinant Factor IX and Von Willebrand Factor. Based on Hemophilia Type, the market is segmented into Hemophilia A and Hemophilia B. Based on End User, the market is segmented into Hospitals, Clinics and Research Organizations. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Recombinant Coagulation Factors Market

The Recombinant Coagulation Factors market is experiencing notable growth driven by a sustained rise in research and development investments and funding within the pharmaceutical and biotechnological sectors. Leading companies in this market are heavily focused on developing advanced technological products, which enhances the adoption of Recombinant Coagulation Factors in both developed and emerging economies worldwide. This trend in increased utilization is further fueled by a growing number of product approvals for innovative recombinant coagulation factors, significantly contributing to the overall expansion of the global market for these essential therapeutic agents.

Restraints in the Recombinant Coagulation Factors Market

The growth of the recombinant coagulation factors market is hindered by several key factors. Primarily, the high cost associated with hemophilia treatment presents a significant barrier, especially when more affordable plasma coagulation treatments are readily accessible in the market. Additionally, the availability of alternative therapies that serve as substitutes for recombinant coagulation factors further exacerbates this challenge. As patients and healthcare providers often seek cost-effective solutions, the competition posed by these alternatives may limit the market's expansion. Consequently, these factors contribute to a more complex landscape for recombinant coagulation factor adoption and utilization.

Market Trends of the Recombinant Coagulation Factors Market

The global recombinant coagulation factors market is experiencing significant growth driven by an increasing prevalence of blood disorders, particularly hemophilia, and the rising adoption of advanced recombinant technologies in treatment modalities. Patients and healthcare providers are gravitating towards recombinant coagulation factors due to their improved safety profile, lower risk of viral transmission, and enhanced therapeutic efficacy compared to traditional therapies. Additionally, ongoing innovation in product formulation and delivery mechanisms, alongside a growing awareness of treatment options and patient-centric healthcare initiatives, are further propelling market expansion. This trend reflects a robust shift in the approach towards managing blood coagulation disorders globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Recombinant Coagulation Factors Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Recombinant Factor VIII
• Recombinant Factor IX
• Von Willebrand Factor

Global Recombinant Coagulation Factors Market Size by Hemophilia Type & CAGR (2026-2033)

• Market Overview
• Hemophilia A
• Hemophilia B

Global Recombinant Coagulation Factors Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Research Organizations

Global Recombinant Coagulation Factors Market Size & CAGR (2026-2033)

• North America (Product Type, Hemophilia Type, End User)
  • US
  • Canada
• Europe (Product Type, Hemophilia Type, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Hemophilia Type, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Hemophilia Type, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Hemophilia Type, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Swedish Orphan Biovitrum AB (Sobi) (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Grifols, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kedrion S.p.A. (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Octapharma AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio Products Laboratory Ltd. (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LFB S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GC Pharma (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CSL Limited (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Freeline Therapeutics (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sangamo Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations